ArticleInternational journal of clinical oncology2026

Efficacy and safety of bevacizumab-combined single-agent chemotherapy for platinum-resistant ovarian cancer that recurred during PARP inhibitor treatment.

Eriko Takatori et al.PubMed ↗Publisher ↗

No numbers read from the abstract.